AACR to split virtual annual meeting into two parts

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

The American Association for Cancer Research has split its virtual annual meeting into two sessions, which will be held in April and in June.

“AACR has been closely monitoring the rapid escalation of the COVID-19 pandemic,” the AACR board said in a statement. “The health and safety of all annual meeting attendees and the patients and communities they serve are the AACR’s highest priorities. Therefore, the AACR board of directors has made the decision not to move forward with an in-person annual meeting in August, and instead to present segments of the meeting program in two AACR virtual annual meetings.”

Here is how the sessions will be split:

  • April 27-28, 2020: AACR Virtual Annual Meeting I. This virtual meeting will feature a selection of high-impact proffered paper presentations. The program will include a number of clinical trial plenary sessions featuring more than 30 oral presentations along with perspectives on the science behind the clinical trials by expert discussants; clinical trial poster sessions; several minisymposia that showcase basic and translational science; and three New Drugs on the Horizon symposia that include first disclosures of innovative small molecules and biologics that have recently entered phase I clinical trials. Access to AACR Virtual Annual Meeting I will be made freely available. The abstracts of these proffered paper presentations will be posted online at 12:01 a.m. EDT (U.S.) on Monday, April 27.

  • June 22-24, 2020: AACR Virtual Annual Meeting II. The second virtual annual meeting will present thousands of proffered papers in minisymposia and in an e-poster platform. This meeting will also include an exciting opening plenary session with presentations on the latest developments in tumor biology and genetics (including the microenvironment), early detection, precision oncology, and cancer immunotherapies; the Presidential Address; the Presidential Select Symposium on precision pediatric cancer medicine; scientific merit and distinguished public service award lectures from individuals who have made extraordinary contributions to the cancer field; and a comprehensive educational program featuring about 70 educational sessions and methods workshops. Further details on the program, information regarding registration for AACR virtual annual meeting II, and guidance in obtaining any refunds of registration fees for the in-person April 2020 annual meeting will be communicated as soon as possible. Abstracts of the proffered paper presentations presented in this virtual meeting will be posted online at 12:01 a.m. EDT (U.S.) on Friday, May 15.

Table of Contents

YOU MAY BE INTERESTED IN

Shearwood McClelland III’s grandfather was a ditchdigger who dreamed that his six Black daughters would become doctors. McClelland’s mother did not disappoint—she became the first Black woman board-certified in maternal fetal medicine in the history of the United States.  Now, McClelland is the chief medical officer of Cancer Health Equity at the University of Oklahoma...

As oncology enters a new era of precision medicine, the Food and Drug Administration’s evolving biomarker strategy aims to ensure that life-saving therapies are tailored to individual patient needs, fostering safer and more effective treatments.  Historically, therapies were approved with broad indications based on overall efficacy, even when outcomes for biomarker-positive and -negative patients were...

In the evolving landscape of pediatric oncology, survivorship research has become an essential component of our mission to improve long-term patient outcomes. At City of Hope, we are focused on not only curing childhood cancers but also ensuring that survivors live the healthiest lives possible. A significant part of my research has been dedicated to mitigating the long-term toxicities of cancer therapy—particularly cardiovascular complications that can arise decades after treatment.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login